HTG Molecular Diagnostics (HTGMQ) Stock Statistics & Valuation Metrics

HTG Molecular Diagnostics has a market cap or net worth of $221.00. The enterprise value is $5.42M.

HTG Molecular Diagnostics has 2,214,233 shares outstanding. The number of shares has decreased by -2.65% in one year.

HTG Molecular Diagnostics’s return on equity (ROE) is -4.01 and return on invested capital (ROIC) is -151.07%.

The current PE Ratio of HTG Molecular Diagnostics is -0.01. HTG Molecular Diagnostics’s PEG ratio is <0.01.

In the last 12 months, HTG Molecular Diagnostics had revenue of 6.37M and earned -21.59M in profits. Earnings per share was -24.28.

In the last 12 months, operating cash flow was -6.39M and capital expenditures -6.24K, giving a free cash flow of -6.39M billion.

HTG Molecular Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

HTG Molecular Diagnostics upcoming earnings date is May 8, 2025, TBA Not Confirmed.

HTG Molecular Diagnostics as a current ratio of 1.89, with Debt / Equity ratio of 46.95%

In the past 12 months, HTG Molecular Diagnostics has paid 10.84K in taxes.

HTG Molecular Diagnostics EV to EBITDA ratio is 0.35, with an EV/FCF ratio of 0.39.

HTG Molecular Diagnostics has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $0.00 billion.

Gross margin is 53.60%, with operating margin of -327.19%, and net profit margin of -339.20%.

The average price target for HTG Molecular Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―